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Aim The metabolically healthy obese (MHO) phenotype refers to obese individuals with a favourable metabolic profile. Its
prognostic value is unclear and may depend on the health outcome being examined. We examined the association of
MHO phenotype with incident cardiovascular disease (CVD) and type 2 diabetes.
Methods
and results
Body mass index and metabolic health, assessed using the Adult Treatment Panel-III (ATP-III) criteria, were assessed on
7122 participants (69.7% men) from the Whitehall II study, aged 39–63 years in 1991–93. Incident CVD (coronary heart
disease or stroke) and type 2 diabetes were ascertained from medical screenings (every 5 years), hospital data, and regis-
try linkage until 2009. A total of 657 individuals (9.2% of the cohort) were obese and 42.5% of these were classified as
MHO in 1991–93. Over the median follow-up of 17.4 years, there were 828 incident cases of CVD and 798 incident
cases of type 2 diabetes. Compared with metabolically healthy normal weight individuals, MHO subjects were at
increased risk for CVD (HR ¼ 1.97, 95% CI: 1.38–2.80) and type 2 diabetes (3.25, 95% CI: 2.32–4.54). There was
excess risk in metabolically unhealthy obese compared with MHO for type 2 diabetes (1.98, 95% CI: 1.39–2.83) but
not CVD (1.23, 95% CI: 0.81–1.87). Treating all measures as time varying covariates produced similar findings.
Conclusion For type 2 diabetes, the MHO phenotype is associated with lower risk than the metabolically unhealthy obese, but for
CVD the risk is as elevated in both obesity phenotypes.
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Introduction
Obesity1 and metabolic syndrome (MetS)2,3 are major public health
problems worldwide which frequently co-exist and define obese indi-
viduals ‘at-risk’ of adverse health outcomes. Recent studies have iden-
tified a subset of obese individuals who have a low burden of
adiposity-related metabolic abnormalities compared with ‘at risk’
obese individuals, the so-called ‘metabolically healthy obese’ (MHO)
phenotype.4–8 Depending on the definition used for metabolic
status, a total of 10–40% of obese individuals9,10 have the MHO
phenotype with a good metabolic profile characterized by high
levels of insulin sensitivity, low prevalence of hypertension, and a
favourable fasting glucose, lipid, and inflammation profile.10
The extent to which the MHO phenotype is associated with a
lower risk of adverse health outcomes remains the subject of
debate. Some studies show this to be the case11,12 particularly, com-
pared with at-risk obese, whereas other studies showa higher risk for
mortality9,13,14 and cardiovascular disease (CVD)11,15,16 in MHO
compared with metabolically healthy normal weight (MH-NW) sub-
jects. Overall, the evidence is inconsistent, and the extant research
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has several limitations. One, the manner in which metabolic health is
defined might be critically important. We previously used five pos-
sible definitions to show a better prognosis in MHO compared
with ‘at risk’ obese only when metabolic health was defined using
insulin resistance, for all other definitions, including the widely used
Adult Treatment Panel-III (ATP-III) definition, the risk of mortality
was similar in all obese individuals.9 However, another report,
albeit with a shorter follow-up, showed MHO phenotype to be asso-
ciated with a lower risk of CVD even using the ATP-III definition.11
Two, it is important to consider potential effect modifications as a
function of the length of follow-up as every 2 obese-years has been
shown to increase mortality risk by 6%.17 Thus, longer follow-ups
may better assess the risk associated with obesity, irrespective of
metabolic health status. Three, it is possible that the specific health
outcome examined plays a role. Outcomes such as type 2 diabetes
are closely tied to parameters used to define metabolic health
making it likely that the MHO phenotype carries less risk for type 2
diabetes than CVD.
To better understand the role of MHO as a risk factor for diseases
with major public health relevance, we examined the association of
the MHO phenotype, defined using the ATP-III criteria, with incident
CVD and type 2 diabetes, over a 17-year follow-up period.
Methods
Study population
Data were drawn from the Whitehall II study, an on-going prospective
cohort study established in 1985 on 10 308 London-based office staff
(6895 males and 3413 females). Details of the cohort and its follow-up
have been described previously.18 Briefly, all office staff aged 35–55
years in 20 civil service departments in London, UK, were invited to par-
ticipate. In total, 73% of those invited agreed to participate at baseline
(1985–88) which consisted of a clinical examination and a self-
administered questionnaire. Subsequent waves of clinical data collection
took place in 1991–93, 1997–99, 2002–04, and 2007–09. Metabolic
health wasfirst assessed in 1991–93, the baseline for the present analysis,
and repeated in 1997–99 and 2002–04. All the participants provided
written consent and the University College London ethics committee
approved the study.
Baseline examination (1991–93)
Body mass index
Weight was measured in underwear to the nearest 0.1 kg on digital
Soehnle electronic scales (Leifheit AS, Nassau, Germany). With the par-
ticipant standing erect in bare feet with head in the Frankfurt plane, height
was measured to the nearest 1 mm using a stadiometer. Reproducibility
of the weight and height measurements over 1 month [correlation
coefficient ¼ between-subject variability/total (between + within
subject) variability], undertaken on 331 participants, was 0.99 for both
weight and height. Body mass index (BMI) was calculated by dividing
weight (in kg) by height (in m2) and categorized using the WHO classifi-
cation:19 ,18.5 kg/m2 (underweight), 18.5–24.9 kg/m2(standard
weight), 25–29.9 kg/m2 (overweight) ≥30 kg/m2 (obese), with the
under 18.5 category (n ¼ 80) removed from the analysis.
Metabolic factors
We used standard operating protocols to measure ATP-III components
to define metabolic status.2 Blood pressure was measured twice in
the sitting position after 5 min of rest with a Hawksley random-zero
sphygmomanometer (Lynjay services Ltd, Worthing, UK). The average
of the two readings was taken to be the measured blood pressure. The
venous blood was taken in the fasting state or at least 5 h after a light,
fat-free breakfast before undergoing a 2-h 75-g oral glucose tolerance
test (OGTT). Serum for lipid analyses was refrigerated at 248C and
assayed within 72 h. High-density lipoprotein-cholesterol (HDL-c) was
measured by precipitating non-HDL-cholesterol with dextran sulfate-
magnesium chloride using a centrifuge and measuring cholesterol in the
supernatant. Serum triglyceride was determined by the enzymatic colori-
metric method (glycerol-3-phosphate oxidase/phenol and aminophena-
zone). Blood glucose was measured using the glucose oxidase method20
(YSI MODEL 2300 STAT PLUS Analyzer, YSI Corporation, Yellow
Springs, OH, USA) (mean coefficient of variation: 2.9–3.3%). Data on
names of medications provided by the participants were coded using
the British National Formulary to identify anti-hypertensive and
lipid-lowering drugs, and medication for diabetes.
Participants who met ,2 of the following four criteria were con-
sidered metabolically healthy: high triglycerides (≥1.7 mmol/L) or
lipid-lowering drugs, elevated systolic blood pressure (≥130 mmHg)
or diastolic blood pressure (≥85 mmHg) or anti-hypertensive drugs,
high fasting glucose (≥5.6 mmol/L) or medications for diabetes (insulin
and oral anti-diabetic) and low HDL-cholesterol (,1.04 mmol/L for
men and ,1.29 mmol/L for women). The waist circumference criterion
was not used because of collinearity with BMI.
We used this definition alongside data on BMI to create six pheno-
types: MH-NW, metabolically healthy overweight, MHO, MU-NW,
metabolically unhealthy overweight (MU-OW) and metabolically un-
healthy obese (MUO).
Covariates
Our analyses were adjusted for socio-demographic variables, behaviour-
al factors and medications, and procedures related to CVD morbidities.
Socio-demographic variables included age, sex, ethnicity (white vs. non-
white), marital status (single, married/cohabiting, divorced, widowed)
and occupational position, a three level variable representing high (ad-
ministrative), intermediate (professional or executive), and low (clerical
or support) grades. This measure is a comprehensive marker of socio-
economic status (SES) and is related to salary, social status, and level of
responsibility at work. Behavioural factors included smoking status
(never, current, or ex-smoker), alcohol intake [assessed via questions
on the number of alcoholic drinks consumed in the last 7 days and cate-
gorized as: no alcohol (none or,1 unit/week), moderate drinkers (1–14
units/week in women and 1–21 units/week in men), heavy drinkers (.14
units in women and .21 units in men)], physical activity (categorized as
‘active’≥2.5 h/weeks of moderate or≥1 h/weekof vigorous physical ac-
tivity, ‘inactive’ ,1 h/week of moderate and ,1 h/week of vigorous
physical activity or ‘moderately active’ if not active or inactive), and con-
sumption of fruits and vegetables (assessed using the question ‘how often
do you eat fresh fruit or vegetable?’ and response were on an two-point
scale: ≥1 fruit or vegetable/day or, 1 fruit or vegetable/day. Cardiovas-
cular disease medication included nitrates and anti-platelet; procedures
consisted of graft replacement of coronary artery, anastomosis of arter-
ies, angioplasty of coronary artery, drugs eluting-stents. Missing data on
covariates in 1991–93 (,1%) and at one of the follow-ups (,5%)
were replaced with data from the phase immediately before or after
that phase.
Covariates over the follow-up, (1997–99,
2002–04, and 2007–09)
All covariates, including BMI and metabolic health, were assessed repeat-
edly over the follow-up. These measures were used as time varying
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covariates in the sensitivity analysis in order to assess whether changes in
these factors over the course of the follow-up influenced the results.
Outcome ascertainment
Incidence of CVD and type 2 diabetes was assessed over the follow-up
from 1991–93 to 2009, a median follow-up of 17.5 years.
Cardiovascular disease
Cardiovascular disease events included fatal CHD [defined by the Inter-
national Classification of Diseases (ICD) 9 codes 410 to 414 or ICD 10
codes I20 to 25], first non-fatal myocardial infarction (MI), first definite
angina, and stroke. Fatal CHD was assessed by flagging participants at
the National Health Service (NHS) Central Registry, which provided in-
formation on the date and cause of death. Non-fatal MI was determined
using data from questionnaires, study electrocardiograms (ECGs), hos-
pital acute ECGs, cardiac enzymes, and physician records following multi-
national monitoring of trends and determinants in CVD criteria.21
Definite angina was assessed based on the participant’s reports of symp-
toms22 with corroboration in medical records for nitrate medication use
or abnormalities on arresting ECG, an exercise ECG or coronary angio-
gram. We excluded angina cases that were based solely on self-reported
data. Stroke included first subarachnoid haemorrhage, intracerebral
haemorrhage, cerebral infarction, and not specified stroke (ICD-10
codes I60–I64), and transient cerebral ischaemic attacks (ICD-10
codes G45). The cases were ascertained from participants’ general prac-
titioners, information extracted from hospital medical records by study
nurses, or data from the NHS Hospital Episode Statistics (ES) database
obtained after linking the participants’ unique NHS identification
numbers to this national database. Self-reported stroke cases without
clinical verification were excluded.
Type 2 diabetes
In 1991–93, after the initial venous blood sample, an OGTT (75 g anhyd-
rous glucose) was administered after an overnight fast or in the afternoon
after no more than a light fat-free breakfast eaten before 08:00 h. A
secondblood samplewas taken2 h later. Subsequent clinical assessments
for type 2 diabetes took place in 1997–99, 2002–04, and 2007–09. The
definition of diabetes used was a 2-h glucose tolerance test finding of at
least 200 mg/dL (≥11.1 mmol/L) or, if the 2-h post-load value was
missing, a fasting glucose level of 126 mg/dL (≥7.0 mmol/L) or physician-
diagnosed diabetes and/or use of diabetes medication. The date of diag-
nosis of diabetes was assigned according to the interval method as the
midpoint between the first visit with a diagnosis of diabetes and the last
visit without diabetes.23
Statistical analysis
The characteristics of the sample are presented as mean+ SD or per-
centage when appropriate, by metabolic status and as a function of BMI
categories. We used ANOVA to test for differences between groups in
baseline characteristics for continuous variables and the x2 test for
dichotomous measures.
Participants were followed until whicheverevent occurred first: death,
incident disease (CVD/type 2 diabetes) or the end of follow-up (2009).
We used logistic regression to examine the extent to which BMI and
metabolic status influenced attrition in the study sample over the follow-
up. The Cox proportional-hazard regression model with age as the time-
scale was used to examine the relationship between BMI categories,
ATP-III components, metabolic status, the six phenotypes described
aboveand first CVD and then type 2 diabetes. The assumption of propor-
tional hazards was checked by examining the interaction term between
the BMI-metabolic status phenotypes and logarithm of the follow-up
time. For the CVD outcome, it was P ¼ 0.10 and for type 2 diabetes it
was P ¼ 0.39, supporting the proportional hazards assumption. The
interaction term between ethnicity (P for interaction .0.60) and sex
(P. 0.36) and BMI-metabolic status phenotypes revealed no differ-
ences, allowing us to combine them in the analysis.
In thefirst setof analyses,weused theMH-NWpersonsas the referent
category. We first present survival curves with age as the timescale using
Kaplan–Meier survival functions in order to enable visual inspection of
trends. Hazard ratio (HR) and 95% confidence intervals (95% CI) were
first adjusted for sex, occupational position, marital status and ethnicity
and then further for smoking status, alcohol intake, physical activity,
fruit and vegetable consumption, CVD medication and procedures.
We then ran a second set of analyses, stratified by BMI category to
allow us to compare the risk of CVD and type 2 diabetes as a function
of metabolic health status in each category. The metabolically healthy
group, within each BMI category, was the reference in these analyses.
Sensitivity analyses
We undertook a series of analyses to assess the robustness of our findings.
One, we excluded angina from the definition of CVD to examine whether
the association between BMI-metabolic status and CVD outcome was
similar when CVD was defined using MI, stroke, and CVD death. Two,
we re-ran the analysis for the CVD outcome with CHD and stroke in sep-
arate analyses to ensure that the results were consistent across both out-
comes. Three, we repeated the Cox proportional-hazard regression used
in the main analysis, but this time with BMI-metabolic phenotypes and all
other measures (including CVD medication and procedures) over the
follow-up treated as time varying covariates to assess the impact of
changes over time in these measures on the associations with CVD and
type 2 diabetes. Of the 7122 participants with data in 1991–93, 5447
had complete data at all subsequent waves of data collection prior to
being censored on thedate of the CVD/type 2 diabetesorat end of follow-
up in 2009. The remaining 1675 participants were censored at the last date
at which they had complete data. Four, in order to examine whether
changes in metabolic health affected risk of CVD and type 2 diabetes, we
created two time windows: one between the 1991–93 and 1997–99 clin-
ical assessments for change in the exposure, the other between 1997–99
and 2007–09 for outcome ascertainment. This analysis was restricted to
the metabolically unhealthy and obese or overweight in 1991–93 in
order to compare risk of CVD and type 2 diabetes between those who
remained metabolically unhealthy and those who became metabolically
healthy between 1991–93 and 1997–99. We also examined whether
weight loss in this group affected risk of CVD and type 2 diabetes by
comparing risk of CVD and type 2 diabetes between those who remained
overweightorobeseandthosewhobecamenormalweight.Analyseswere
undertaken using STATA 11 (StataCorp. College Station, TX, USA).
Reported P-values are two-tailed and P-values ,0.05 were considered
to be statistically significant.
Results
Of the 8815 participants who took part in the 1991–93 examination
(the baseline of the analyses reported here), 1693 were excluded for
one or more of the following reasons at baseline: BMI , 18.5 kg/m2
(n ¼ 80), missing data on BMI-metabolic status phenotype (n ¼ 995),
prevalent type 2 diabetes (n ¼ 262), or prevalent CVD (n ¼ 296); a
further 588 persons were excluded because of missing data on type
2 diabetes status over the follow-up. The final sample consisted of
7122 participants. Compared with those excluded, participants
included in the analyses were younger (49.3 vs. 51.6 years), more
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likely to be men (69.7 vs. 64.4%), married or cohabiting (76.8 vs.
73.0%), physically active (44.7 vs. 41.1%), and to have a higher occu-
pational position (39.5 vs. 30.6%), all P, 0.01.
Compared with normal weight persons, overweight (1.19, 95% CI:
1.03, 1.37) and obese (1.29, 95% CI: 1.03, 1.62) persons had a higher
odds-ratio of non-participation at the end of the follow-up. This was
not the case for poor metabolic status (OR ¼ 1.11, 95% CI: 0.96,
1.28). Crucially, the interaction term between BMI and metabolic
status (P ¼ 0.65) suggested that non-participation was not signifi-
cantly different in the six phenotypes defined by BMI and metabolic
health.
Table 1 shows baseline characteristics of the participants included in
the analysis by metabolic status and BMI categories; 70.4% (n ¼ 5015)
of the participants were metabolically healthy and 9.2% (n ¼ 657)
were obese. The MHO phenotype represented 3.9% (n ¼ 279) of
the total analytic sample and 42.5% of the obese population. They
were more often women and had better health behaviours in terms
of smoking, alcohol, and fruit and vegetables consumption compared
with MUO. Triglycerides, LDL-cholesterol, fasting glucose, and
blood pressure were higher in metabolically unhealthy persons,
whileHDL-cholesterolwashigher inMHO.Duringamedian follow-up
of17.4years,828 incidentCVD(4.5%intheMHOand8%intheMUO)
and 798 type 2 diabetes (6.0% in the MHO and 16.0% in the MUO)
events occurred; 58.2% of CVD and 42.1% of type 2 diabetes cases
occurred in the first 10 years of follow-up.
Table 2 presents the associations of BMI categories, ATP-III com-
ponents, and metabolic status with incident CVD and type 2 diabetes.
Compared with normal weight individuals, both the overweight
(HR ¼ 1.36, 95% CI: 1.17, 1.57) and obese (HR ¼ 1.89, 95% CI:
1.51, 2.37) had an increased risk of incident CVD; the same was
true for type 2 diabetes, albeit the associations were stronger. All
components of the ATP-III criteria were associated with incident
CVD and type 2 diabetes, blood pressure being most strongly asso-
ciatedwithCVDand fasting glucosemost stronglywith type2diabetes.
Compared with metabolically healthy individuals (irrespective of
obesity), metabolically unhealthy individuals had an increased risk of
incident CVD (HR ¼ 1.97, 95% CI: 1.72, 2.27) and type 2 diabetes
(HR ¼ 3.22, 95% CI: 2.79, 3.73).
The Kaplan–Meier survival curves for cumulative survival free
from, respectively, incident CVD and type 2 diabetes as a function
of BMI-metabolic status phenotypes are shown in Figures 1 and 2.
These survival curves differ significantly from each other over the
follow-up (log-rank test,P, 0.001).The HRandCIof the association
between the BMI-metabolic status phenotypes and incident CVD
and type 2 diabetes are shown in Table 3; Supplementary material
online, Figure S1 summarizes these findings. Compared with the
MH-NW group, the five other groups were at an increased risk of
incident CVD and type 2 diabetes with the associations being
consistently stronger for type 2 diabetes.
In Table 4, we present the association between metabolic status
and incident CVD and type 2 diabetes in analysis stratified by BMI cat-
egory; the metabolically healthy group was the reference within each
strata of BMI. In normal weight and overweight individuals, the meta-
bolically unhealthy had a higher risk of CVD and type 2 diabetes.
However, in obese individuals the metabolically unhealthy were not
at an increased risk of incident CVD (HR ¼ 1.26, 95% CI: 0.83, 1.92)
but had a higher risk of type 2 diabetes (HR ¼ 1.99, 95% CI: 1.39,
2.84). Supplementary material online, Tables S1 and S2 show that
when angina was removed from the definition of CVD, the results
were similar to those reported in the main analysis (Tables 3 and 4).
Results of analyses with CHD and stroke analysed separately
rather than a composite CVD outcome (Supplementary material
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Sample characteristics at baseline (1991–93) as a function of metabolic health status and body mass index
Metabolically healthy (n5 5015) Metabolically unhealthy (n 5 2107)
Normal weight Overweight Obese Normal weight Overweight Obese
n (%) 3100 (43.5) 1636 (23.0) 279 (3.9) 649 (9.1) 1080 (15.2) 378 (5.3)
Male, % 67.1 66.4 34.8 86.3 84.1 62.4
Age, years 48.6 (6.0) 49.4 (5.9) 49.7 (5.9) 50.1 (6.0) 50.5 (6.0) 49.9 (5.8)
White, % 93.1 90.2 82.4 89.7 91.7 91.0
Married/cohabiting, % 75.2 78.2 67.7 79.8 80.4 74.6
High SES, % 42.5 35.6 25.2 45.4 39.5 33.2
Never smokers, % 53.8 50.4 49.6 49.2 46.1 40.3
No alcohol, % 17.8 17.4 31.5 20.0 15.8 24.1
Physically active, % 45.7 43.6 34.1 48.2 45.1 41.0
≥1 fruit and vegetable/day, % 64.7 60.4 65.2 59.8 56.3 54.4
Triglycerides, mmol/L 1.0 (0.4) 1.2 (0.5) 1.2 (0.5) 2.1 (1.4) 2.3 (1.4) 2.4 (1.6)
HDL-cholesterol, mmol/L 1.6 (0.4) 1.5 (0.3) 1.5 (0.3) 1.2 (0.4) 1.2 (0.3) 1.2 (0.3)
LDL-cholesterol, mmol/L 4.2 (0.9) 4.5 (1.0) 4.3 (1.1) 4.6 (1.0) 4.7 (1.1) 4.6 (1.0)
Fasting glucose, mmol/L 5.1 (0.4) 5.1 (0.4) 5.0 (0.4) 5.5 (0.5) 5.5 (0.5) 5.5 (0.5)
Systolic blood pressure, mmHg 115.6 (12.0) 118.6 (11.3) 121.8 (13.4) 127.7 (14.4) 128.4 (12.8) 130.8 (12.3)
Diastolic blood pressure, mmHg 75.9 (8.4) 78.9 (8.1) 81.0 (9.1) 83.9 (8.9) 85.9 (8.5) 87.2 (8.6)
Values are mean (SD) unless otherwise indicated.
SES, socioeconomic status.
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online, Table S3) were consistent across both these outcomes and
similar to those for CVD. Analyses that treated BMI-metabolic status
phenotypeand all over covariates (including CVD medicationand pro-
cedures administered to persons over the course of the follow-up) as
time varying covariates (Supplementary material online, Tables S4–S6)
yielded similar results to those reported, respectively, in Tables 2–4.
The final analysis on a subset of metabolically unhealthy
overweight/obese in 1991–93 compared those who remained
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table2 The association of body mass index, Adult Treatment Panel-III components and metabolic status (1991–93) with
cardiovascular disease and type 2 diabetes over the follow-up (until 2007–09)
CVD HR (95% CI) (n 5 828) Type 2 diabetes HR (95% CI) (n5 798)
Body mass index
Normal weight 1.0 (ref) 1.0
Overweight 1.36 (1.17–1.57) 1.75 (1.49–2.05)
Obese 1.89 (1.51–2.37) 3.90 (3.19–4.76)
ATP-III components
Blood pressure ≥130/85 mmHg or medication 1.74 (1.51–2.00) 1.60 (1.39–1.85)
Triglycerides ≥1.7 mmol/L or medication 1.66 (1.44–1.91) 2.51 (2.17–2.90)
HDL-cholesterol ,1.03 (,1.29) mmol/L (women) 1.68 (1.44–1.97) 2.15 (1.84–2.51)
Fasting glucose ≥5.6 mmol/L or medication 1.25 (1.06–1.47) 2.64 (2.27–3.06)
Metabolic status (defined using ATP-III criteria)
Healthy 1.0 1.0
Unhealthy 1.97 (1.72–2.27) 3.22 (2.79–3.73)
Analyses adjusted for sex, socioeconomic status, marital status, ethnicity physical activity, smoking, alcohol, fruits and vegetables consumption, CVD medication and procedures.
HR, hazard ratio; CI, confidence interval.
Figure 1 Kaplan–Meier survival curves showing the association between body mass index-metabolic status phenotypes and cardiovascular
disease events.
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metabolically unhealthy until 1997–99 (n ¼ 89, rate ¼ 15.34 per
1000 person-years for CVD and n ¼ 128, rate ¼ 23.82 per 1000
person-years for type 2 diabetes) to those became metabolically
healthyover this period (n ¼ 45, rate ¼ 13.16per1000person-years
for CVD; n ¼ 32, rate ¼ 9.62 per 1000 person-years for type 2 dia-
betes). These results suggest that becoming metabolically healthy
Figure 2 Kaplan–Meier survival curves showing the association between body mass index-metabolic status phenotypes and type 2 diabetes.
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Table 3 The association of body mass index -metabolic health status (1991–93) with cardiovascular disease and type 2
diabetes at the end of follow-up (2007–09)
Events/n Ratea Model 1 HR (95% CI) Model 2 HR (95% CI)
CVD
Metabolically healthy normal weight 239/3100 4.81 1.0 (ref) 1.0
Metabolically healthy overweight 164/1636 6.38 1.24 (1.01–1.51) 1.24 (1.01–1.51)
Metabolically healthy obese 37/279 8.93 1.99 (1.40–2.83) 1.95 (1.37–2.77)
Metabolically unhealthy normal weight 116/649 12.20 2.14 (1.71–2.68) 2.08 (1.66–2.60)
Metabolically unhealthy overweight 206/1080 13.00 2.25 (1.86–2.72) 2.23 (1.84–2.70)
Metabolically unhealthy obese 66/378 11.95 2.49 (1.89–3.27) 2.44 (1.85–3.21)
Type 2 diabetes
Metabolically healthy normal weight 154/3100 3.37 1.0 (ref) 1.0
Metabolically healthy overweight 136/1636 5.75 1.57 (1.24–1.98) 1.56 (1.24–1.97)
Metabolically healthy obese 48/279 12.96 3.21 (2.29–4.49) 3.22 (2.30–4.51)
Metabolically unhealthy normal weight 110/649 12.46 3.24 (2.52–4.15) 3.20 (2.49–4.10)
Metabolically unhealthy overweight 222/1080 15.29 3.96 (3.21–4.89) 3.90 (3.16–4.82)
Metabolically unhealthy obese 128/378 26.58 7.12 (5.60–9.06) 6.92 (5.43–8.81)
Model 1 is adjusted for sex, socioeconomic status, marital status, and ethnicity.
Model 2 ¼ Model 1 + physical activity, smoking, alcohol, fruits and vegetables consumption, CVD medication and procedures.
HR, hazard ratio; CI, confidence interval.
aPer 1000 person-years.
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did not lead to significantly lower risk of CVD (HR ¼ 0.89, 95% CI:
0.62, 1.28) but was associated with a lower risk of type 2 diabetes
(HR ¼ 0.39, 95% CI: 0.26, 0.58). Of the 574 metabolically unhealthy
overweight/obese subjects in 1991–93, only 13 lost weight to
become normal weight in 1997–99. No further analysis could be
undertaken as there were 3 CVD events and 1 case of type 2 diabetes
in this group of 13 individuals.
Discussion
In this prospective study of over 7000 adults, 9.2% of the population
was obese and nearly half of them were ‘metabolically healthy’, using
the ATP-III criteria to define metabolic health. The main findings are
that MHO persons were at an increased risk of incident CVD and
type 2 diabetes, followed-up over 17 years, compared with the
MH-NWindividuals. However, compared with the MUO, MHO indi-
viduals were not at a lower risk of incident CVD although their risk of
type 2 diabetes was lower.These findings were replicatedwhen CVD
endpoints were defined excluding angina and when BMI-metabolic
status phenotypes were treated as time varying covariates. Although
risk factors for stroke and coronary heart disease do not overlap
completely, we found similar patterns of associations when stroke
andCHD wereanalysed as separateoutcomes rather than acompos-
ite CVD outcome.
The finding that MHO individuals were at an increased risk of inci-
dent CVD compared with MH-NWis consistent with some,11,13,15,16
but not all previous studies.24,25 Like our study, the first set of studies
had a large number of events in the analysis and a long-follow-up
period (average of .10 years) while the latter studies had relatively
few events in the analysis and shorter follow-up (average of ,10
years). The inconsistency in these results may be due to the fact
that there may be as long as a 10–15-year time lag before the evi-
dence of the effect of the metabolic health becomes apparent.26
However, a recent large-scale study (n ¼ 71 527) reported increased
riskof MI and ischaemic heart disease in MHO comparedwith normal
weight subjects without MetS even with a short-follow-up period
(median of 3.6 years).16
Our findings show that the prognosis of MHO is outcome-specific.
We considered two incident chronic diseases, CVD and type 2 dia-
betes, in order to examine this issue. There is no ambiguity in the
results obtained for CVD compared with the MH-NW group; the
MHO have higher risk of CVD and this risk is no different with that
in the MUO. This suggests that obesity outweighs the impact of meta-
bolic status for risk of CVD. Our finding is quite consistent with data
from a recently published study which concluded that MetS is no
more valuable than BMI in identifying individuals at risk for CVD.16
However, the pattern is different for type 2 diabetes where although
the MHO group had higher risk compared with the normal weight
metabolically healthy phenotype, as reported previously,24,25 their
risk was significantly lower than that in the MUO. Thus for type 2 dia-
betes, where metabolic health is an important predictor, the risk in
the MHO group is lower than that in the MUO group.
Multiple definitions of metabolic health have been used in defining
the MHO phenotype.10 In a previous study, we showed that the
prevalence of the MHO phenotype varies as a function of the defin-
ition used,9 contributing in part to the inconsistencies found in the as-
sociation of this phenotype with health outcomes. We used the
ATP-III definition of MetS2 which is based on established cut-off
and not dependent on risk distribution in the population under
study to define metabolic health as in some definitions.24,27,28
Given the prevalence of the MHO phenotype in obese popula-
tions, emphasis is increasingly placed onunderstanding the character-
istics and potential mechanisms underlying their healthy metabolic
profile. It has been suggested that there are hormones that play a
role in allowing certain obese individuals to maintain a healthy
profile; and that location, metabolic activity and histological
characteristics rather than amount of adipose tissue may partially
determine metabolic health among obese individuals.29 Results
from previous studies suggest that MHO individuals have been
obese for fewer years compared with their MUO counterparts,30
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Table 4 The association of metabolic health status (1991–93) with cardiovascular disease and type 2 diabetes in analyses
stratified by body mass index categories
Events/n Ratea CVD HR (95% CI) Events/n Ratea Type 2 diabetes
HR (95% CI)
Normal weight (BMI: 18.5–24.9 kg/m2)
Metabolically healthy 239/3100 4.81 1.0 (ref) 154/3100 3.37 1.0
Metabolically unhealthy 116/649 12.20 2.04 (1.62–2.56) 110/649 12.46 3.12 (2.42–4.02)
Overweight (BMI: 25–29.9 kg/m2)
Metabolically healthy 164/1636 6.38 1.0 136/1636 5.75 1.0
Metabolically unhealthy 206/1080 13.00 1.81 (1.47–2.24) 222/1080 15.29 2.58 (2.07–3.22)
Obese (BMI ≥ 30 kg/m2)
Metabolically healthy 37/279 8.93 1.0 48/279 12.96 1.0
Metabolically unhealthy 66/378 11.95 1.26 (0.83–1.92) 128/378 26.58 1.99 (1.39–2.84)
HR, hazard ratio; CI, confidence interval.
Analyses adjusted for sex, socioeconomic status, marital status, ethnicity, physical activity, smoking, alcohol, fruits and vegetables consumption, CVD medication, and procedures.
aPer 1000 person-years.
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they display a lower level of C-reactive protein,7 high adiponectin
concentrations,31 high levels of insulin sensitivity despite having a
high accumulation of body fat.4 There is also some evidence that
MHO individuals are fitter than their metabolically unhealthy coun-
terparts.12 This favourable profile might reduce their risk of type 2
diabetes but the risk of CVD is no different with that observed in
the MUO.
Notable strengths of this study include its large sample size and the
assessment of outcomes over a 17-year follow-up period. We were
able to show consistency in results in analyses that took into account
change in metabolic health status and/or BMI and all other covariates
in the analysis (including treatments and procedures administered)
over the course of the follow-up. We were also able to show consist-
ency in the results in analyses when stroke and CHD were analysed
separately rather than a composite CVD outcome. To minimize the
potential for confounding, we adjusted for several covariates, includ-
ing SES, ethnic group, alcohol consumption, marital status, physical
activity, smoking, dietary behaviour, treatments, and procedures.
Loss to follow-up for the outcomes is low because data come from
linkage to mortality and hospital episodes database for 10 297 of
the 10 308 participants at study inception. The study also has some
limitations. First, the occupational nature of the cohort of civil ser-
vants which did not include blue-collar workers and unemployed
individuals and may thus not be representative of the general popu-
lation limiting the generalizability of our findings. However, our
sample covers a wide socioeconomic range with.10-fold difference
between the highest and lowest salaries. Secondly, despite the size of
the sample, there is lack of ethnic diversity in the cohort, although
tests suggested no heterogeneity in associations as a function of eth-
nicity. A further caveat is the extent to which changes in treatments
and medical intervention to reduce risk of CVD in studies with a long
follow-up can be accounted for in the analyses. We adjusted for these
aspects using time varying covariates with results, suggesting that
changes in treatment do not affect the results. However, we recog-
nize that it is not possible to fully control for changes in treatment
over time by covariate adjustment. Finally, we examined only type
2 diabetes and CVD in the present analysis and it is possible that
the associations with other health outcomes, cancer, for example,
follow a different pattern.
In conclusion, we show that one source of inconsistency in the
prognosis of metabolically healthy, but obese phenotype is the spe-
cific health outcome under consideration. The MHO phenotype
carries less risk for type 2 diabetes when compared with MUO
even though the risk is greater than that in the MH-NW persons.
However, for CVD the prognosis in MHO individuals is as poor as
that in the MUO. Better understanding of the health risks associated
with the MHO phenotype requires closer attention to how metabol-
ic health is defined and certainly the health outcome under consider-
ation. Metabolically healthy obesity does not appear to be a benign
condition, making it important to promote prudent weight loss in
overweight/obese individuals and control of modifiable risk factors.
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